March 7, 2022
Pharmaceutical company
Mallinckrodt ARD LLC will pay
$260 million to resolve allegations that it violated the False Claims Act in the sale and marketing of its drug H.P. Acthar Gel. The government intervened in whistleblower actions alleging that Mallinckrodt and its predecessor Questcor Pharmaceuticals Inc. knowingly underpaid state Medicaid programs by improperly calculating amounts it owed under the Medicaid Drug Rebate Program, and unlawfully used a foundation as a conduit to subsidize co-payments. With respect to the Medicaid rebate claims, which represent $234.7 million of the settlement, defendants were alleged to have calculated rebate amounts as if Acthar was a “new drug” first marketed in 2013, rather than a drug that had been approved since 1952. By using 2013 for Acthar’s Base Date Average Manufacturer Price (AMP), the company ignored price increases prior to 2013 and fraudulently reduced Acthar drug rebates. With respect to the copayment fraud claims, which represent $26.3 million of the settlement, defendants were alleged to have violated the Anti-Kickback Statute by subsidizing copayments through payments to three funds that Mallinckrodt had a foundation set up to induce Medicare-reimbursed purchases of Acthar, using the subsidies to counteract doctor and patient concerns about the drug’s high cost. The whistleblower in the Medicaid rebate case,
James Landolt will receive an award of $24.7 million, representing 20% of the $123.6 million federal share of that settlement; the relator’s share for the state share of the settlement was not announced. The whistleblowers in the copayment case,
Charles Strunck and
Lisa Pratta, will receive an award of
$4.9 million, representing 19% of that settlement. The settlement includes a five-year corporate integrity agreement (CIA) with monitoring provisions.
DOJ;
USAO MA;
USAO EDPA